Skip to content
value.today

Acceleron Pharma Inc.

Total raised
$62 M
4 rounds on record
Latest round
$10 M
Sep 2013
First round on record
Dec 2009
Today
Private
See the company page

Acceleron Pharma Inc. is listed today as Acceleron Pharma Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Acceleron Pharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2013$10 MNo. 4$10 to $50 million

Acceleron Pharma Inc.: Raise no. 4, Sep 2013

Investors in this round

1 investor had bought by the notice of Sep 27, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 27 investors are named for Acceleron Pharma Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Knopf · Executive Officer, Director
  • Kevin F. Mclaughlin · Executive Officer
  • Matthew L. Sherman · Executive Officer
  • Robert G. Steininger · Executive Officer
  • Steven G. Ertel · Executive Officer
  • Anthony B Evnin · Director
  • Edwin M. Kania, Jr. · Director
  • George S. Golumbeski · Director
  • Jean M. George · Director
  • Joseph S. Zakrzewski · Director
  • Richard F. Pops · Director
  • Terrance G. Mcguire · Director
  • Tom G. Maniatis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John L. Knopf, Chief executive officer and president. Source: SEC Form D, newest notice filed Sep 27, 2013. Read the notice at the SEC.

equitySEC
Dec 2011$30 MNo. 3$10 to $50 million

Acceleron Pharma Inc.: Raise no. 3, Dec 2011

Investors in this round

47 investors had bought by the notice of Jan 4, 2012: 47 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 27 investors are named for Acceleron Pharma Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Knopf · Executive Officer, Director
  • Kevin F. Mclaughlin · Executive Officer
  • Matthew L. Sherman · Executive Officer
  • Robert L. Steininger · Executive Officer
  • Steven L. Ertel · Executive Officer
  • Anthony B Evnin · Director
  • Carl L. Gordon · Director
  • Edwin M. Kania · Director
  • George S. Golumbeski · Director
  • Jean M. George · Director
  • Joseph S. Zakrzewski · Director
  • Richard F. Pops · Director
  • Terrance G. Mcguire · Director
  • Tom W. Maniatis · Director
  • Wylie W. Vale · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kevin F. Mclaughlin, Chief financial officer and senior vice president. Source: SEC Form D, newest notice filed Jan 4, 2012. Read the notice at the SEC.

equitySEC
Jun 2010$10 MNo. 2$10 to $50 million

Acceleron Pharma Inc.: Raise no. 2, Jun 2010

Investors in this round

48 investors had bought by the notice of Jul 21, 2010: 48 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 27 investors are named for Acceleron Pharma Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $12 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jasbir Seehra · Executive Officer
  • John Knopf · Executive Officer, Director
  • Matthew L. Sherman · Executive Officer
  • Peter Courossi · Executive Officer
  • Anthony L. Evnin · Director
  • Carl L. Gordon · Director
  • Ed L. Kania · Director
  • Jean L. George · Director
  • Pat L. Gage · Director
  • Richard L. Pops · Director
  • Terry L. Mcguire · Director
  • Tom L. Maniatis · Director
  • Wylie L. Vale · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter Courossi, Chief financial officer. Source: SEC Form D and 1 amendment, newest notice filed Jul 21, 2010. Read the notice at the SEC.

equity, optionsSEC
Dec 2009$11 MNo. 1$10 to $50 million

Acceleron Pharma Inc.: Raise no. 1, Dec 2009

Investors in this round

40 investors had bought by the notice of Dec 15, 2009: 40 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 27 investors are named for Acceleron Pharma Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jasbir Seehra · Executive Officer
  • John Knopf · Executive Officer, Director
  • Matthew L. Sherman · Executive Officer
  • Peter Courossi · Executive Officer
  • Anthony L. Evnin · Director
  • Carl L. Gordon · Director
  • Ed L. Kania · Director
  • Jean L. George · Director
  • Pat L. Gage · Director
  • Richard L. Pops · Director
  • Terry L. Mcguire · Director
  • Tom L. Maniatis · Director
  • Wylie L. Vale · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter Courossi, Chief financial officer. Source: SEC Form D, newest notice filed Dec 15, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Acceleron Pharma Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2013).

    SEC Form D · Sep 2013

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2013

That is all the official record says: Acceleron Pharma Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Acceleron Pharma Inc. are on record.

Investors#

27 named in official filings. Open an investor to see everything it has backed.

Investors in Acceleron Pharma Inc.
InvestorKindAmountRoundRoleSource
Advanced Technology Ventures VII(B), L.P.Venture capitalnot statednot statedHeld Series A, B, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Advanced Technology Ventures VII(C), L.P.Venture capitalnot statednot statedHeld Series A, B, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Advanced Technology Ventures VII LPVenture capitalnot statednot statedHeld Series A, B, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Advanced Technology Ventures VI, L.P.Venture capitalnot statednot statedHeld Series A, B, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Agtc Advisors Fund LPFund or asset managernot statednot statedHeld Series A, B, C, D and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
AGTC Partners, L.P.Fund or asset managernot statednot statedHeld Series A, B, C, D and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Applied Genomic Technology Capital Fund LPFund or asset managernot statednot statedHeld Series A, B, C, D and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
ATV Alliance 2003, L.P.Fund or asset managernot statednot statedHeld Series A, B, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
ATV Associates VII, L.L.C.Othernot statednot statedHeld Series A, B, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
ATV Associates VI, L.L.C.Othernot statednot statedHeld Series A, B, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
ATV Entrepreneurs VII, L.P.Fund or asset managernot statednot statedHeld Series A, B, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
ATV Entrepreneurs VI, L.P.Fund or asset managernot statednot statedHeld Series A, B, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Celgene Corp /de/Companynot statednot statedHeld Series C-1, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Flagship Pioneering, LLCFund or asset managernot statednot statedHeld Series A, B, C, D and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
NewcoGen Group, Inc.Companynot statednot statedHeld Series A, B, C, D and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series B, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Orbimed Capital GP II LLCFund or asset managernot statednot statedHeld Series B, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Polaris Venture Management Co IV LLCVenture capitalnot statednot statedHeld Series A, B, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Polaris Venture Partners Entrepreneurs Fund IV LPVenture capitalnot statednot statedHeld Series A, B, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Polaris Venture Partners IV LPVenture capitalnot statednot statedHeld Series A, B, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Tom ManiatisPersonnot statednot statedHeld Series A, B, C and D preferred stock, director (Form 3, 2013)SEC Form 3
VEF Management IV, LLCFund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Venrock Associates IV L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Venrock Entrepreneurs Fund IV L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Venrock Management IV, LLCFund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Venrock Partners, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Venrock Partners Management, LLCFund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 48 investors.

Largest shareholders today

Institutions holding Acceleron Pharma Inc. shares, as of Jun 30, 2026.

Source: SEC Form 13F holdings reports · as of Jun 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Acceleron Pharma Inc.
NameRoleNamed in
John KnopfExecutive officerSep 2013
Kevin F. MclaughlinExecutive officerSep 2013
Matthew L. ShermanExecutive officerSep 2013
Robert G. SteiningerExecutive officerSep 2013
Steven G. ErtelExecutive officerSep 2013
Robert L. SteiningerExecutive officerJan 2012
Steven L. ErtelExecutive officerJan 2012
Jasbir SeehraExecutive officerJul 2010
Peter CourossiExecutive officerJul 2010
Anthony B EvninDirectorSep 2013
Edwin M. Kania, Jr.DirectorSep 2013
George S. GolumbeskiDirectorSep 2013
Jean M. GeorgeDirectorSep 2013
John KnopfDirectorSep 2013
Joseph S. ZakrzewskiDirectorSep 2013
Richard F. PopsDirectorSep 2013
Terrance G. McguireDirectorSep 2013
Tom G. ManiatisDirectorSep 2013
Carl L. GordonDirectorJan 2012
Edwin M. KaniaDirectorJan 2012
Tom W. ManiatisDirectorJan 2012
Wylie W. ValeDirectorJan 2012
Anthony L. EvninDirectorJul 2010
Ed L. KaniaDirectorJul 2010
Jean L. GeorgeDirectorJul 2010
Pat L. GageDirectorJul 2010
Richard L. PopsDirectorJul 2010
Terry L. McguireDirectorJul 2010
Tom L. ManiatisDirectorJul 2010
Wylie L. ValeDirectorJul 2010

About

Company in Cambridge, United States.